secwatch.observer — SEC 8-K summary
======================================

Issuer:     MBX Biosciences, Inc. (MBX)
CIK:        0001776111
Form:       8-K
Filed at:   2025-06-16T23:59:59+00:00
Accession:  0000950170-25-086546
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MBX Biosciences submits IND for MBX 4291, once-monthly GLP-1/GIP obesity prodrug
--------------------------------------------------------------------------------

- IND submitted to FDA for MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug for obesity.
- Designed for once-monthly administration to potentially improve adherence and GI tolerability.
- Phase 1 trial expected to start Q3 2025 in healthy overweight volunteers.
- Candidate developed using MBX's proprietary PEP platform technology.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025086546/0000950170-25-086546-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1776111/000095017025086546/mbx-20250616.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-086546

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer